Postoperative complication rate, similar to that of general patients
(Seoul = Yonhap News) Reporter Jandi Kim = Even if you take immunosuppressive drugs after organ transplantation, a study has found that there is no problem with gastric cancer surgery.
Professor Kim Hyung-il of Yonsei Cancer Hospital’s Gastrointestinal Surgery Department and Wonju Severance Christian Hospital’s Transplant Surgery Professor Kim Deok-ki announced on the 18th that they investigated 41 patients who underwent organ transplantation, took immunosuppressive drugs, and underwent gastric cancer surgery.
Organ transplant patients who usually take immunosuppressive drugs are often concerned that the risk of complications and infection is high if their immunity is weakened by excision of cancer tissue or administration of chemotherapy.
Accordingly, the research team compared and analyzed the surgical outcomes of 41 patients (35 kidney transplants, 5 liver transplants, 1 heart transplant) who underwent gastric cancer surgery after organ transplantation and 205 general gastric cancer patients with similar conditions such as gender and age. .
As a result, the total rate of short-term complications within 30 days after gastrectomy was 22.0% for transplant patients and 20.0% for general patients in the control group.
There was no significant difference in the rate of long-term complications 30 days after gastrectomy, 4.9% for transplant patients and 1.0% for controls.
There was no significant difference between the 20.0% of the transplant group and 19.0% of the control group in the results of tracking the recurrence rate of cancer for 58 months.
The research team explained that there was no significant difference in the incidence of long-term and short-term complications between organ transplant patients and general patients.
However, in the 58-month follow-up of the recurrence rate, 26 organ transplant patients with stage 1 stomach cancer did not have cancer recurrence, but the recurrence rate of 15 organ transplant patients with stage 2 or 3 stomach cancer reached 75%, twice that of general patients.
In this study, the research team pointed to the fact that the rate of anticancer drug administration was significantly lower in organ transplant patients with stage 2 or 3 stomach cancer.
Their anticancer drug administration rate was 26.6%, which was significantly lower than the general patient’s anticancer drug administration rate of 95.8%. The research team interpreted these results as reluctance to administer anticancer drugs because of anxiety that anticancer drugs could cause side effects to transplanted organs.
Professor Kim Hyung-il said, “Through this study, organ transplant patients are less likely to be concerned about complications from gastric cancer surgery. Transplant patients should actively undergo chemotherapy.”
The research results were published in the European Journal of Surgical Oncology, an international academic journal.
Unauthorized reproduction-redistribution prohibited>
2021/10/18 10:05 Send